AFI FY23: headline NPAT down 14% but underlying earnings up 8.6% ex BHP special

What changed

Reported revenue from operating activities fell 14.0% to A$310.2m and statutory NPAT fell 14.1% to A$309.8m, with profit before tax down 11.6% to A$330.8m. The company flags that the prior year included a A$74.9m one-off dividend from the BHP unification, and that on an adjusted basis underlying profit was up 8.6% year on year. Operating cash flow moved the other way, rising 14.4% to A$317.7m, and cash on the balance sheet grew to A$165.4m against unchanged A$10.0m of bank debt, leaving a net cash position of A$155.4m (prior: A$134.6m). Total assets expanded 8.4% to A$9b and equity 8.1% to A$7.6b. The interim dividend was lifted to 11c from 10c.

What matters

• The 14% headline fall is a base-effect optical illusion. Once the A$74.9m BHP special is removed from the FY22 base, underlying investment income grew 8.6%. This is the most important read and dominates any sequential narrative.
• Cash generation outpaced accounting earnings. Operating cash of A$317.7m exceeded NPAT of A$309.8m and grew 14.4% while reported earnings fell, suggesting the dividend stream received in cash was healthier than the P&L comparison implies.
• Balance sheet is strengthening, not stretching. Net cash rose by roughly A$20.8m, gross borrowings are static, and equity grew A$567.1m – consistent with portfolio revaluation supporting NTA rather than any gearing-up of the book.

Expectations

No forward-looking quantified target or forecast portfolio income was provided, so there is no explicit yardstick to grade this against. On seasonality, HY23 contributed 58.3% of full-year revenue and 52.8% of full-year NPAT, pointing to a modestly first-half-weighted shape – unsurprising given the Australian interim-dividend cycle that drives AFI's receipts. The result is consistent with a portfolio that is still growing its ordinary dividend income stream, but the release does not support any claim about the trajectory of future special dividends, which were the swing factor in FY22.

Quality of result

Earnings quality is mixed but broadly reassuring for an LIC. PBT is the cleaner measure here – the effective tax rate rose to 6.2% from 3.6%, so NPAT fell faster than PBT (–14.1% vs –11.6%), a 2.5pp gap driven by tax rather than operations. Operating cash exceeding NPAT and growing 14% argues the underlying dividend flow is genuine cash, not accrual-led. The caveat is that A$74.9m of the FY22 base was a non-recurring merger distribution, so the reported decline is almost entirely a base effect rather than deterioration; equally, the FY23 result itself benefits from nothing comparable, meaning the 8.6% underlying uplift is the durable read. ROE slipped to 4.1% from 5.2%, but for an LIC that reflects equity growth from portfolio revaluation outpacing reported earnings, not a margin issue.

Unresolved

• What portion of FY23 income was itself special/one-off (capital-sourced distributions), given the Board is sourcing 7c of the final dividend from capital gains?
• Full-period dividend total and cash payout ratio cannot be confirmed – only the 11c interim and a reference to a capital-sourced final component are captured here.
• Portfolio-level metrics that matter most for an LIC – NTA per share, management expense ratio for FY23, and portfolio performance versus benchmark – are not in the supplied extract.
• No reconciliation was provided from statutory to the "8.6% up on adjusted prior year" figure, so the adjusted base is asserted rather than verifiable from the extract.

This briefing cannot assess NTA, share-price premium/discount, benchmark-relative portfolio performance, or the sustainability of special-dividend income beyond what the statutory numbers disclose.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.